Laryngeal Cancer Clinical Trial
— SPEAKFREEOfficial title:
Evaluation of a Disposable Hands-Free Heat and Moisture Exchanger (HME) Valve: The Blom-Singer SpeakFree HME Hands Free Valve
NCT number | NCT05349487 |
Other study ID # | 20210501 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | June 28, 2022 |
Est. completion date | June 30, 2025 |
The purpose of the study is to evaluate the new Blom-Singer SpeakFree disposable hands free valve heat and moisture exchanger (HME). The investigators will compare the SpeakFree to other modalities of stomal occlusion (digital occlusion and digital depression of an HME) for patients who communicate with a voice prosthesis as determined by patient preference and satisfaction. In addition, the investigators will compare the SpeakFree to other modalities of stomal occlusion as determined by objective measures of speech and voice parameters (maximum phonation time, syllables per breath, minimum/maximum phonation pressures, and a clinician rating of voice quality using a visual analog scale).
Status | Recruiting |
Enrollment | 36 |
Est. completion date | June 30, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Participants who have undergone a total laryngectomy who have and use a voice prosthesis as their primary form of communication for at least 3 months prior to study enrollment. - Participants must have had at least 2 voice prosthesis management visits from a speech pathologist at the University of Miami prior to study enrollment. - Participants must have fully healed suture lines. - Participants must demonstrate fluent tracheoesophageal speech (i.e., maximum phonation time of at least 5 seconds during 3 consecutive trials) - Current HME use for a minimum of 1 month - Participants willing to complete the survey and provide a signed Informed Consent Form - Males and non-pregnant females over the age of 18 Exclusion Criteria: - Participants who do not have a voice prosthesis. - Participants who have dysarthria. - Participants who are currently receiving treatment for head and neck cancer. - Participants who have an underlying neurologic condition potentially impacting speech. |
Country | Name | City | State |
---|---|---|---|
United States | University of Miami | Miami | Florida |
Lead Sponsor | Collaborator |
---|---|
University of Miami |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Satisfaction as measured by VAS | Patient preference and satisfaction will be measured using a visual Analog Scale (VAS) ranging in score from 1-10 with a higher score indicating greater satisfaction with the device. | Up to 1 month | |
Primary | Voice Quality: Patient Rating | Voice Quality will be measured using a visual Analog Scale ranging in score from 1-10 with a higher score indicating that the patient feels their voice quality is better with the device. | Up to 1 month | |
Secondary | Change in Maximum Phonation Time | Maximum phonation time (MPT) is a clinical measurement of the longest time a person can phonate a vowel in seconds. | Baseline, 1 month | |
Secondary | Change in Syllables Per Breath | Participants' number of syllables per breath while reading a standardized reading passage will be measured and reported. | Baseline, 1 month | |
Secondary | Pressure Needed to Phonate | Minimal and maximal pressures will be reported using a manometer while the participant counts from 1 to 15. | Baseline | |
Secondary | Change in Voice Quality: Clinician Rating | The clinician will rate participant's voice quality using VAS. VAS has a total score ranging from 1 to 10 with the higher score indicating that the clinician feels that participant's voice quality is better with the device. | Baseline, 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01089803 -
Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer
|
N/A | |
Completed |
NCT00026975 -
Efficacy of Hyperbaric Oxygen Therapy in Laryngectomy Patients
|
Phase 2 | |
Completed |
NCT01435252 -
A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab
|
Phase 2 | |
Recruiting |
NCT04174950 -
Perioperative ERAS Based Nursing Intervention for Laryngeal Cancer Patients
|
N/A | |
Recruiting |
NCT05857202 -
Oxidative Stress and Inflammation Biomarkers in Surgically Treated Patients With Laryngeal Cancer
|
||
Recruiting |
NCT06077643 -
Workshops and Exchange Groups for Laryngectomized Patients
|
||
Not yet recruiting |
NCT06137378 -
European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]
|
Phase 2 | |
Active, not recruiting |
NCT02586207 -
Pembrolizumab in Combination With CRT for LA-SCCHN
|
Phase 1 | |
Recruiting |
NCT02012699 -
Integrated Cancer Repository for Cancer Research
|
||
Recruiting |
NCT05375266 -
Immune Biomarker Study for Head and Neck Cancer
|
||
Completed |
NCT03134976 -
Wound Complications in Head and Neck Surgery
|
||
Recruiting |
NCT04650919 -
Aortic Laryngeal Rehabilitation Graft
|
N/A | |
Recruiting |
NCT05830240 -
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer
|
Early Phase 1 | |
Terminated |
NCT02437513 -
NewBreez for Airway Protection in Head and Neck Cancer Patients With Chronic Aspiration
|
N/A | |
Completed |
NCT01633541 -
Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer
|
Phase 2 | |
Completed |
NCT01332682 -
Resistance Training and Physical Functioning in Head and Neck Cancer Patients
|
Phase 1 | |
Terminated |
NCT00011492 -
Patient Evaluation for Head and Neck Surgery Branch Studies
|
||
Completed |
NCT00467948 -
Comparison of 2 Cefazolin Prophylactic Protocol in Laryngectomy Patients
|
Phase 3 | |
Recruiting |
NCT06024980 -
Using the Subglottic Pressure to Predict the Dysphagia After Partial Laryngectomy
|
N/A | |
Recruiting |
NCT03747783 -
Nomograms to Precisely Predict Conditional Risk of Survival for Patients With Laryngeal Cancer
|